Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312299 | 0.83 | NOTUM (0.58) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13616470 | 0.82 | MAPT (0.39) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4320548 | 0.80 | NOTUM (0.61) | MAPTCYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL2904156 | 0.77 | NOTUM (0.64) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4307364 | 0.75 | NOTUM (0.56) | MAPTNPC1RAB9AL3MBTL1LMNA | |
| SCHEMBL5304351 | 0.74 | NOTUM (0.64) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4314667 | 0.74 | CYP11B1 (0.45) | MAPTCYP2C19NOTUMDRD2DRD4 | |
| SCHEMBL4317470 | 0.73 | NOTUM (0.56) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4307346 | 0.73 | HDAC3 (0.41) | MAPTHTTALDH1A1NOTUMDRD2 | |
| SCHEMBL4307369 | 0.73 | DRD2 (0.51) | MAPTNPC1RAB9ANOTUMPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | MAPT 3175/4885CYP1A2 1054/4885CYP3A4 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.